What Is Grade III Oligodendroglioma — and Why Sequencing Matters
A Grade III oligodendroglioma, also called anaplastic oligodendroglioma, is a primary brain tumor that grows from oligodendrocytes, the cells that normally form the protective myelin sheath around nerve fibers. Under the 2021 World Health Organization (WHO) classification, this tumor is defined by two molecular features: a mutation in the IDH1 or IDH2 gene and a co-deletion of chromosomal arms 1p and 19q. These features matter. They affect how the tumor behaves, how it responds to treatment, and how long patients tend to live.
Grade III shows higher mitotic activity, meaning the tumor divides faster than Grade II. Because of this, most neuro-oncologists agree that adjuvant treatment after surgery is needed. The real question is which comes first: radiation therapy or chemotherapy, and whether to give both right away or save one for later.
According to the National Cancer Institute, radiation therapy and alkylating chemotherapy—either temozolomide or the three-drug combination of procarbazine, lomustine, and vincristine (PCV)—are used in nearly all patients with Grade III oligodendroglioma. The order and timing, though, can differ significantly depending on your tumor's biology and your overall health.
The Landmark Trials That Defined the Standard of Care
The treatment framework for Grade III oligodendroglioma was shaped mainly by two large Phase III clinical trials: RTOG 9402, conducted in the United States, and EORTC 26951, conducted in Europe. Both enrolled patients over many years. Their joint final analysis, published in 2022, provides the most reliable evidence available in this disease.
The two trials tested a very similar question but differed in how they ordered treatment:
- RTOG 9402 gave PCV chemotherapy before radiation—a chemotherapy-first approach.
- EORTC 26951 gave radiation first, followed by up to six cycles of PCV chemotherapy.
Both were compared against radiation therapy alone. In both trials, the combination of radiation with PCV—regardless of which came first—showed a meaningful benefit specifically in patients whose tumors had the 1p/19q co-deletion.
Long-term results from RTOG 9402 found that in patients with 1p/19q-codeleted tumors, those who received PCV plus radiation had a median overall survival of 14.7 years, compared to 7.3 years for radiation alone. In patients without the co-deletion, the two treatment arms showed no meaningful difference in survival.
The joint final analysis of both trials confirmed this conclusion: radiation plus PCV chemotherapy gives a clear, lasting survival advantage for patients with co-deleted Grade III oligodendroglioma. Importantly, whether chemotherapy came before or after radiation did not appear to change the overall magnitude of benefit—the combination itself was what mattered most.
This insight matters clinically. It suggests that sequencing may be more flexible than previously assumed, as long as patients ultimately receive both treatments as part of their plan.
Radiation First: When This Approach Is Favored
The radiation-first approach—used in EORTC 26951—involves delivering focal radiation to the tumor bed and surrounding area, typically over four to six weeks, followed by chemotherapy once radiation is complete. This has historically been the more common starting point in clinical practice.
Clinical scenarios where starting with radiation may make the most sense include:
- The tumor is causing significant symptoms such as worsening seizures, language difficulties, or focal weakness that require rapid local control.
- There are contrast-enhancing areas on MRI, suggesting more aggressive growth within the tumor.
- The patient has characteristics that may make upfront multi-drug chemotherapy harder to tolerate, such as borderline blood counts or specific medical conditions.
- The tumor shows features associated with less predictable response to chemotherapy alone.
Following radiation, PCV or temozolomide chemotherapy is added. In correctly identified 1p/19q-codeleted patients, this combined strategy is associated with the longest documented survival outcomes in Grade III oligodendroglioma based on available trial data.
Chemotherapy First: The Case for Deferring Radiation
A chemotherapy-first approach, sometimes called radiation deferral, is a strategy some neuro-oncologists consider for carefully selected patients. The primary motivation is the long-term cognitive risk of brain radiation.
Radiation to the brain, even when precisely targeted, may cause late neurotoxicity over years. These effects can include memory loss, slowed processing speed, and difficulty with attention and executive function. For patients who may live 10 to 20 years after treatment, these long-term quality-of-life concerns matter. Research has examined whether radiation can be safely deferred in select oligodendroglioma patients, with chemotherapy used as initial treatment and radiation held in reserve until progression.
The rationale rests on how well alkylating agents work against 1p/19q-codeleted tumors. Because these drugs are effective, some clinicians think that chemotherapy alone might control the disease long enough to deliver radiation later, using newer, more precise technology, and avoiding early radiation risks in younger patients.
It is important to be clear: chemotherapy-first with radiation deferral is not the established standard of care for Grade III oligodendroglioma. The randomized evidence that supports the survival benefit of combined treatment included radiation in all study designs. If you are interested in exploring this approach, the conversation must happen with a neuro-oncologist at an experienced center—ideally one that participates in clinical trials evaluating this question prospectively.
PCV vs. Temozolomide: A Separate but Related Debate
Once sequencing is addressed, another practical question remains: which chemotherapy regimen should you receive?
PCV—procarbazine, lomustine (CCNU), and vincristine—is the regimen used in both RTOG 9402 and EORTC 26951. Its side-effect profile can be demanding. Many patients experience fatigue, nausea, low blood cell counts, and peripheral nerve symptoms. Despite this, PCV has the most robust long-term data for Grade III oligodendroglioma with 1p/19q co-deletion.
Temozolomide (TMZ) is an oral chemotherapy agent that is generally easier to take. It became the standard treatment for glioblastoma after 2005, and many oncologists began using it for Grade III gliomas as well—largely due to its more manageable side-effect profile and convenience.
A clinical debate published in the journal Neuro-Oncology notes that temozolomide, while widely used in practice, has not been tested against PCV in a large randomized trial specifically for 1p/19q-codeleted Grade III oligodendroglioma. RTOG 9402 and EORTC 26951 showed survival benefits with PCV. Whether TMZ produces equivalent long-term disease control in this exact tumor type remains an open research question. Many neuro-oncologists currently favor PCV for confirmed codeleted Grade III tumors when a patient can tolerate it, while TMZ may be discussed when PCV's cumulative side-effect burden is a significant concern.
This decision should be individualized and discussed explicitly with your care team, including the relative side-effect risks, your performance status, and your personal priorities.
Why Molecular Testing Is Not Optional
Every decision described in this article—the sequencing, the chemotherapy choice, the radiation timing—rests entirely on knowing your tumor's confirmed molecular identity. A tumor that looks like an oligodendroglioma under the microscope may lack IDH mutation, 1p/19q co-deletion, or both. Under current WHO 2021 criteria, a tumor without these features is not classified as an oligodendroglioma, and its optimal treatment may be entirely different.
The American Brain Tumor Association's patient guide on oligodendroglioma emphasizes that molecular markers are now central to how these tumors are classified and treated. If your pathology report does not include confirmed IDH mutation testing and 1p/19q co-deletion analysis, or if you are uncertain whether those tests were completed, ask questions before starting any adjuvant therapy.
Consider requesting a molecular pathology review and second opinion on your tumor genetics if there is any uncertainty about the diagnosis. Getting the molecular classification right the first time protects every downstream treatment decision you and your team will make.
Emerging Options: IDH Inhibitors and Open Clinical Trials
For patients with Grade 2 IDH-mutant gliomas, a related but distinct category, vorasidenib, an oral IDH1/IDH2 inhibitor, received FDA approval in August 2024. The National Cancer Institute has covered vorasidenib's role in IDH-mutant low-grade glioma, where the INDIGO trial showed it meaningfully delayed time to progression compared with placebo.
Vorasidenib is not currently approved for Grade III oligodendroglioma. The INDIGO trial specifically enrolled patients with Grade 2 disease. However, research is actively investigating IDH-targeted approaches in higher-grade IDH-mutant gliomas. This remains an evolving area where clinical trials may offer access to promising agents before they become standard therapy.
If you are interested in pursuing a trial at the time of initial diagnosis before committing to standard radiation and chemotherapy, discuss eligibility with your care team. For guidance on matching your molecular profile to an appropriate study, see our article on choosing a clinical trial for Grade III tumors based on molecular mutations.
If recurrence occurs after initial therapy, a different set of options and decisions comes into play. Learn more in our overview of treatment options after oligodendroglioma recurrence following chemoradiation.
Factors Your Team Will Weigh When Recommending a Sequence
Neuro-oncologists weigh several overlapping factors when recommending whether to start with radiation, chemotherapy, or both together. The most common include:
- Extent of surgical resection: A gross total resection may give more flexibility in timing adjuvant therapy. Significant residual tumor typically calls for more prompt combined treatment.
- Presence of contrast enhancement: Enhancement on post-operative MRI suggests active, aggressive tumor behavior and often supports earlier radiation.
- Confirmed 1p/19q co-deletion status: This feature predicts exceptional chemosensitivity and is central to any rationale for deferring radiation.
- Patient age and cognitive baseline: Younger patients with many years ahead of them may have more to gain from strategies that delay radiation-related neurotoxicity.
- Neurological symptom burden: Significant symptoms typically favor prompt local treatment rather than a chemotherapy-first approach.
- Performance status and medical history: PCV requires a reasonable baseline of bone marrow reserve and nerve health to be safely administered.
No single algorithm fits every patient. Oligodendroglioma management should be reviewed by a multidisciplinary tumor board with neurosurgeons, radiation oncologists, neuro-oncologists, and neuroradiologists evaluating your imaging and molecular data together. If you are not already being seen at a center with this infrastructure, consider requesting a referral or a telemedicine consultation at an academic neuro-oncology program that specializes in glioma.
When to Talk to Your Doctor
If you have been newly diagnosed with Grade III oligodendroglioma, bring the following questions to your care team before starting adjuvant treatment:
- Has my tumor been confirmed to have both an IDH mutation and 1p/19q co-deletion? What specific tests were used?
- What is the rationale for starting with radiation versus chemotherapy in my specific case?
- Am I a candidate for radiation deferral, and what are the concrete risks and benefits for my situation?
- Should I receive PCV or temozolomide, and why?
- Are there open clinical trials I should consider before committing to standard chemoradiation?
- Will my case be reviewed by a multidisciplinary tumor board?
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.